| Name | LungLife AI, Inc (DI) |
|---|---|
| Epic | LLAI |
| Isin | USU5500L1045 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 9.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £2.29 | Debt ratio | n/a |
| Shares in issue | 25.49 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -160.99 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -21.2 | 52-week high / low | 8.25p / 90.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | LungLife AI, Inc (DI) |
|---|---|
| Address | 850 New Burton Road, Suite 201, Dover, Delaware, USA, 19904 |
| Telephone | |
| Website | https://www.lunglifeai.com/ |
| Director | Position |
|---|---|
| Mr Paul Carmelo Pagano | CEO |
| Ms Sara Barrington | Non-Executive Director |
| Mr Gordon Roy Davis | Non-Executive Chairman |
| Mr Andrew Norman Boteler | Senior Independent Non-Executive Director |
| Mr David Mark Anderson | Chief Finance Officer |
| Mr James Renwick McCullough | Independent Non-Executive Director |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 5.82 | 5.82 | 5.82 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 6.22 | 6.4 | 6.6 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.47 | 0.61 | 0.74 |
| Cash and equivalents | 2.72 | 3.09 | 9.22 |
| Other current assets and asset held for resale | 0.1 | 4.92 | 5.41 |
| Total of all assets | 9.52 | 15.02 | 21.97 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 1.45 | 1.48 | 1.18 |
| Long term liabilities | 0.16 | 0.4 | 0.65 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.61 | 1.88 | 1.84 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 7.91 | 13.14 | 20.13 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | n/a | n/a | n/a |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -85.12 | -79.7 | -72.1 |
| Share premium account | 91.27 | 91.27 | 91.26 |
| Total equity | 7.91 | 13.14 | 20.13 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -5.63 | -7.74 | -7.23 |
| Pre-tax profit | -5.41 | -7.6 | -7.43 |